S2688
RTT - Patient experience and quality of life
ESTRO 2026
including an adapted patient-experience questionnaire, and EORTC QLQ-C30 and QLQ-PAN26 to measure quality of life [1- 3].
Digital Poster 4869 Advances in imaging to assess response in pancreatic cancer (AIR - PANC) – Feasibility of RTT led imaging research Aileen Duffton 1,2 , Lynsey Devlin 1,2 , Stefanie Thomson 3 , Marimuthu Sankaralingam 3 , Kirsty Armstrong 4 , Sarah Allwood-Spiers 5 , Sharon Cave Cave 1 , Algernon Bloom 2 , David Chang 2 , Fieke Froeling 2 , Linda Galbraith Galbraith 6 , Stacey Holloway 2 , David Lewis 2 , Derek Grose 1,2 1 Radiotherapy, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom. 2 Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom. 3 Radiotherapy Physics, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom. 4 Radiology, Queen Elizabeth University Hospital, Glasgow, United Kingdom. 5 Imaging Centre of Excellence, Queen Elizabeth University Hospital, Glasgow, United Kingdom. 6 CRUK RadNet PPI, University of Glasgow, Glasgow, United Kingdom Purpose/Objective: Functional-MRI to detect changes in pancreatic cancer during and after radiotherapy (RT) is under investigation. This requires the patient to have multiple MRI scans throughout their treatment pathway. Abdominal RT, where motion mitigation techniques and robust positioning and immobilisation is required, repeat scans can be challenging. This work reports feasibility of consenting and scanning patients in a response imaging study (AIR-PANC), and patients scan experience. Material/Methods:
Results: 15/17 (88%) patients approached consented to the study. 12/15 (80%) patients completed all scanning procedures, demonstrating feasibility. Of the 3/15 (20%) patients, 1 was no longer fit for treatment, 1 withdrew because of commitment to another clinical trial, 1 withdrew after baseline scan. At baseline, treatment and FU 100%, 91.7% and 100% respectively indicated they didn’t require additional information before their scan i.e. “not at all”. All responses (100%) indicated no additional information on BH instructions were required for all scans (Figure-1).The proportion of participants reporting “moderately” or “very” easy to maintain position was 61.6%, 58.3 and 58.4% at baseline, treatment and FU respectively. Participants indicating they wanted to come out of the scanner before the end of session was 23%, 33.3%, and 25% respectively.
This was a single centre feasibility study (ClinicalTrials.gov IDNCT05727319). Eligible
participants were ≥ 18 years, histologically confirmed pancreatic ductal carcinoma (PDAC), measurable disease on imaging and scheduled for RT (±chemotherapy) or chemotherapy alone (CHEMO). Exclusions were uncontrolled systemic disease, conditions affecting consent/compliance, recent major surgery, MRI contraindications. Primary endpoint was the proportion of patients successfully completing acquisition of baseline and treatment scan.A Simon’s optimal two-stage design was used to evaluate the feasibility of image acquisition. The design assumed 80% power and a one-sided 20% significance level, with a null hypothesis acquisition rate of 50% and an alternative hypothesis rate of 70%.Patients underwent 3 additional MRI scans (baseline, during treatment, and follow up (FU) 4–6 weeks after completing treatment. Timings and sequences for RT and CHEMO only patients are described in table-1. Blood samples were collected at each MRI. Patients were consented for use of surplus from routine diagnostic biopsy tissue. Questionnaires were completed at each MRI,
Made with FlippingBook - Share PDF online